Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.
BACKGROUND: To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG). METHODS: Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and se...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4016135?pdf=render |
| _version_ | 1819083326081728512 |
|---|---|
| author | Shi-Ming Li Ru Chen Yuan Li Zhi-Rong Yang Qiu-Ju Deng Zheng Zhong Moh-Lim Ong Si-Yan Zhan |
| author_facet | Shi-Ming Li Ru Chen Yuan Li Zhi-Rong Yang Qiu-Ju Deng Zheng Zhong Moh-Lim Ong Si-Yan Zhan |
| author_sort | Shi-Ming Li |
| collection | DOAJ |
| description | BACKGROUND: To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG). METHODS: Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events. RESULTS: Seven randomized controlled trials with 685 patients were included. In comparison with timolol, latanoprost reduced absolute IOP in CACG patients by more than 2.3 mmHg (95%CI, 1.8∼2.9, P<0.01), 2.4 mmHg (95%CI, 1.9∼2.9, P<0.01) and 2.5 mmHg (95%CI, 1.6∼3.3, P<0.01) at mean, peak and trough, respectively. As for relative IOP, there is 9.0% (95%CI, 6.6∼11.4, P<0.01), 9.7% (95%CI, 7.6∼11.8, P<0.01), and 10.8% (95%CI, 7.4∼14.3, P<0.01) greater reduction among latanoprost users than among timolol users. The differences were statistically significant at all time points (1, 2, 4, 8, 12, and 24 weeks). More ocular adverse effects (OR = 1.49, 95% CI, 1.05∼2.10, P = 0.02) and less systemic adverse events (OR = 0.46, 95% CI, 0.25∼0.84, P = 0.01) were observed in latanoprost group in comparison with timolol group. CONCLUSION: Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients. |
| first_indexed | 2024-12-21T20:30:47Z |
| format | Article |
| id | doaj.art-bb299a0440ac45e2a7a901e541c8ac24 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T20:30:47Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-bb299a0440ac45e2a7a901e541c8ac242022-12-21T18:51:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9685210.1371/journal.pone.0096852Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.Shi-Ming LiRu ChenYuan LiZhi-Rong YangQiu-Ju DengZheng ZhongMoh-Lim OngSi-Yan ZhanBACKGROUND: To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG). METHODS: Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events. RESULTS: Seven randomized controlled trials with 685 patients were included. In comparison with timolol, latanoprost reduced absolute IOP in CACG patients by more than 2.3 mmHg (95%CI, 1.8∼2.9, P<0.01), 2.4 mmHg (95%CI, 1.9∼2.9, P<0.01) and 2.5 mmHg (95%CI, 1.6∼3.3, P<0.01) at mean, peak and trough, respectively. As for relative IOP, there is 9.0% (95%CI, 6.6∼11.4, P<0.01), 9.7% (95%CI, 7.6∼11.8, P<0.01), and 10.8% (95%CI, 7.4∼14.3, P<0.01) greater reduction among latanoprost users than among timolol users. The differences were statistically significant at all time points (1, 2, 4, 8, 12, and 24 weeks). More ocular adverse effects (OR = 1.49, 95% CI, 1.05∼2.10, P = 0.02) and less systemic adverse events (OR = 0.46, 95% CI, 0.25∼0.84, P = 0.01) were observed in latanoprost group in comparison with timolol group. CONCLUSION: Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients.http://europepmc.org/articles/PMC4016135?pdf=render |
| spellingShingle | Shi-Ming Li Ru Chen Yuan Li Zhi-Rong Yang Qiu-Ju Deng Zheng Zhong Moh-Lim Ong Si-Yan Zhan Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. PLoS ONE |
| title | Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. |
| title_full | Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. |
| title_fullStr | Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. |
| title_full_unstemmed | Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. |
| title_short | Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. |
| title_sort | meta analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of asian populations with chronic angle closure glaucoma |
| url | http://europepmc.org/articles/PMC4016135?pdf=render |
| work_keys_str_mv | AT shimingli metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT ruchen metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT yuanli metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT zhirongyang metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT qiujudeng metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT zhengzhong metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT mohlimong metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma AT siyanzhan metaanalysisofrandomizedcontrolledtrialscomparinglatanoprostwithtimololinthetreatmentofasianpopulationswithchronicangleclosureglaucoma |